Laronidase - BioMarin/Sanofi Genzyme

Drug Profile

Laronidase - BioMarin/Sanofi Genzyme

Alternative Names: Aldurazyme; Alpha-L-iduronidase; BM 101; JC 0498; rh alpha-L-iduronidase

Latest Information Update: 09 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioMarin Pharmaceutical; Genzyme Corporation
  • Developer BioMarin Pharmaceutical; Sanofi Genzyme; University of California at Los Angeles
  • Class Glycoside hydrolases
  • Mechanism of Action Iduronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis I
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mucopolysaccharidosis I

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Mucopolysaccharidosis-I(In children) in USA (Intrathecal, Injection)
  • 08 Aug 2017 Launched for Mucopolysaccharidosis I in Russia and Hong Kong (IV) before August 2017
  • 15 Feb 2017 Interim pharmacodynamics data from a trial in mucopolysaccharidosis type I (Hurler syndrome) released by Sanofi Genzyme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top